JP2018536634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536634A5 JP2018536634A5 JP2018518690A JP2018518690A JP2018536634A5 JP 2018536634 A5 JP2018536634 A5 JP 2018536634A5 JP 2018518690 A JP2018518690 A JP 2018518690A JP 2018518690 A JP2018518690 A JP 2018518690A JP 2018536634 A5 JP2018536634 A5 JP 2018536634A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- reacts
- alkyl
- give
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 37
- 125000000217 alkyl group Chemical group 0.000 claims 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 238000006555 catalytic reaction Methods 0.000 claims 5
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052763 palladium Inorganic materials 0.000 claims 3
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 239000002841 Lewis acid Substances 0.000 claims 2
- 238000007171 acid catalysis Methods 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000007517 lewis acids Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003880 polar aprotic solvent Substances 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- DOZYTHNHLLSNIK-JOKMOOFLSA-M mycophenolate sodium Chemical compound [Na+].OC1=C(C\C=C(/C)CCC([O-])=O)C(OC)=C(C)C2=C1C(=O)OC2 DOZYTHNHLLSNIK-JOKMOOFLSA-M 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510924946 | 2015-12-11 | ||
| CN201510924946.1 | 2015-12-11 | ||
| PCT/CN2016/109036 WO2017097224A1 (zh) | 2015-12-11 | 2016-12-08 | 氮杂环丁烷衍生物、其制备方法及用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536634A JP2018536634A (ja) | 2018-12-13 |
| JP2018536634A5 true JP2018536634A5 (enExample) | 2019-12-19 |
| JP6860267B2 JP6860267B2 (ja) | 2021-04-14 |
Family
ID=59012693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018518690A Active JP6860267B2 (ja) | 2015-12-11 | 2016-12-08 | アゼチジン誘導体、その調製方法、及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10159662B2 (enExample) |
| EP (1) | EP3360878B9 (enExample) |
| JP (1) | JP6860267B2 (enExample) |
| CN (1) | CN108137603B (enExample) |
| DK (1) | DK3360878T3 (enExample) |
| ES (1) | ES2830446T3 (enExample) |
| HK (1) | HK1250707B (enExample) |
| WO (1) | WO2017097224A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1250707B (zh) * | 2015-12-11 | 2020-07-03 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物、其制备方法及用途 |
| EP3572415B1 (en) * | 2017-01-23 | 2024-03-06 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Jak kinase inhibitor and preparation method and use thereof |
| ES2937823T3 (es) | 2017-06-07 | 2023-03-31 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Forma sólida del derivado de azetidina y método de preparación del mismo y uso del mismo |
| SG11202002947TA (en) | 2017-11-03 | 2020-04-29 | Aclaris Therapeutics Inc | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
| US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
| CN113149993A (zh) * | 2017-12-01 | 2021-07-23 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| AR117398A1 (es) * | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| BR112021002479A2 (pt) | 2018-08-10 | 2021-07-27 | Aclaris Therapeutics, Inc. | composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| CN111518096B (zh) * | 2019-02-02 | 2022-02-11 | 江苏威凯尔医药科技有限公司 | 两面神激酶jak家族抑制剂及其制备和应用 |
| WO2020173364A1 (zh) * | 2019-02-27 | 2020-09-03 | 四川科伦博泰生物医药股份有限公司 | 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| AU2020256720B2 (en) | 2019-04-12 | 2022-09-01 | PrimeGene (Beijing) Co. Ltd. | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof |
| CN113727975A (zh) | 2019-05-02 | 2021-11-30 | 阿克拉瑞斯治疗股份有限公司 | 作为jak抑制剂的被取代的吡咯并吡啶 |
| CN110028432A (zh) * | 2019-05-22 | 2019-07-19 | 南京合巨药业有限公司 | 一种（3-氨基-氮杂环丁烷-1-基）-环丙基-甲酮的制备方法 |
| CA3141571A1 (en) * | 2019-05-28 | 2020-12-03 | Mankind Pharma Ltd. | 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP2025509642A (ja) | 2022-03-18 | 2025-04-11 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | アゼチジン誘導体の使用および治療方法 |
| WO2023226822A1 (zh) * | 2022-05-26 | 2023-11-30 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物治疗病毒感染的方法及用途 |
| CN115974864B (zh) * | 2022-12-29 | 2025-09-16 | 苏州汉德创宏生化科技有限公司 | 一种2-(3-氮杂环丁基)噻唑盐的合成方法 |
| WO2024148184A1 (en) * | 2023-01-04 | 2024-07-11 | Aerie Pharmaceuticals, Inc. | Compounds and processes for the preparation of jak inhibitors |
| CN120530118A (zh) * | 2023-01-18 | 2025-08-22 | 北京普祺医药科技股份有限公司 | 一种氮杂环烷烃化合物、药物组合物及其用途 |
| CN116444529B (zh) * | 2023-06-16 | 2023-12-05 | 药康众拓(江苏)医药科技有限公司 | 一种氘代氮杂环丁烷类jak抑制剂及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2380795T3 (es) | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pirrolopiridinas útiles como inhibidores de proteínas quinasas |
| ES2602577T3 (es) * | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| SMT201800137T1 (it) | 2010-03-10 | 2018-07-17 | Incyte Holdings Corp | Derivati di piperidin-4-il azetidina come inibitori di jak1 |
| WO2012177606A1 (en) * | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2013173506A2 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| MA39984B1 (fr) | 2014-04-08 | 2020-12-31 | Incyte Corp | Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné |
| PH12017501538B1 (en) | 2015-02-27 | 2024-02-14 | Incyte Holdings Corp | Salts of p13k inhibitor and processes for their preparation |
| RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
| HK1250707B (zh) * | 2015-12-11 | 2020-07-03 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物、其制备方法及用途 |
-
2016
- 2016-12-08 HK HK18109969.8A patent/HK1250707B/zh unknown
- 2016-12-08 US US15/767,508 patent/US10159662B2/en active Active
- 2016-12-08 CN CN201680059396.4A patent/CN108137603B/zh active Active
- 2016-12-08 EP EP16872413.6A patent/EP3360878B9/en active Active
- 2016-12-08 ES ES16872413T patent/ES2830446T3/es active Active
- 2016-12-08 JP JP2018518690A patent/JP6860267B2/ja active Active
- 2016-12-08 WO PCT/CN2016/109036 patent/WO2017097224A1/zh not_active Ceased
- 2016-12-08 DK DK16872413.6T patent/DK3360878T3/da active
-
2018
- 2018-10-24 US US16/169,780 patent/US20190060291A1/en not_active Abandoned
-
2020
- 2020-01-16 US US16/745,206 patent/US11045455B2/en active Active